UBS Group Lowers ZimVie (NASDAQ:ZIMV) Price Target to $10.00

ZimVie (NASDAQ:ZIMV) had its target price decreased by equities research analysts at UBS Group from $16.00 to $10.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price objective would suggest a potential upside of 10.99% from the company’s current price.

ZIMV has been the topic of several other research reports. B. Riley began coverage on ZimVie in a research note on Thursday, April 10th. They set a “buy” rating and a $16.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of ZimVie in a research report on Wednesday, April 9th.

ZimVie Price Performance

Shares of NASDAQ ZIMV opened at $9.01 on Thursday. The company has a quick ratio of 1.38, a current ratio of 1.94 and a debt-to-equity ratio of 0.57. ZimVie has a fifty-two week low of $8.55 and a fifty-two week high of $22.40. The business has a 50 day moving average price of $9.95 and a two-hundred day moving average price of $12.48. The firm has a market cap of $250.90 million, a PE ratio of -0.69 and a beta of 2.16.

ZimVie (NASDAQ:ZIMV) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.06. The business had revenue of $112.00 million during the quarter, compared to the consensus estimate of $113.10 million. ZimVie had a negative net margin of 77.31% and a positive return on equity of 2.90%. Sell-side analysts expect that ZimVie will post 0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ZimVie

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC raised its position in shares of ZimVie by 2,695.9% during the 1st quarter. AlphaQuest LLC now owns 8,947 shares of the company’s stock worth $97,000 after purchasing an additional 8,627 shares during the period. Quantbot Technologies LP acquired a new stake in ZimVie in the first quarter worth $98,000. SG Americas Securities LLC lifted its stake in ZimVie by 15.7% in the fourth quarter. SG Americas Securities LLC now owns 11,110 shares of the company’s stock valued at $155,000 after buying an additional 1,508 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of ZimVie by 9,039.1% during the first quarter. Jones Financial Companies Lllp now owns 12,612 shares of the company’s stock valued at $136,000 after acquiring an additional 12,474 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in shares of ZimVie during the first quarter valued at $144,000. 95.63% of the stock is currently owned by institutional investors and hedge funds.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.